Right to Try Gives Fentanyl Patients Access to Ibogaine. It Doesn’t Give Them What Keeps Ibogaine Patients Alive.

There’s a version of the Right to Try story that writes itself. A veteran, treatment-resistant, failed every therapy the VA offered, hears that a law exists letting seriously ill Americans access unapproved treatments. He finds an ibogaine provider willing to work under that framework. He gets the treatment stateside, under a doctor’s supervision. He gets better.

That story is real, and it’s incomplete.

The patients most likely to qualify for Right to Try ibogaine access are fentanyl-dependent adults who’ve cycled through medication-assisted treatment without lasting success. And fentanyl-dependent adults are, by a significant margin, the highest-risk category for ibogaine’s most dangerous side effect: a potentially fatal cardiac arrhythmia.

That’s not a knock on ibogaine. It’s a structural problem nobody in the advocacy space seems eager to say out loud.

More than three gates

The advocacy framing presents Right to Try as three requirements: a life-threatening condition, exhausted approved treatments, and ineligibility for a clinical trial. Those are the patient-facing criteria. The full picture has more moving parts.

The prescribing physician must be a licensed MD in good standing with their state licensing authority, and cannot be compensated by the manufacturer for recommending the treatment. The facility must comply with federal human subjects research mandates, which means an IRB framework and documented informed consent procedures. A freestanding retreat or solo practice almost certainly doesn’t qualify without significant compliance infrastructure.

The requirement that gets the least attention is this: the manufacturer has to voluntarily agree to supply the drug. Right to Try doesn’t compel anyone to provide anything. For ibogaine, that means you need a pharmaceutical company or academic sponsor holding an active IND who agrees to release it under RTT. Right now, that sponsor doesn’t exist at scale. DemeRx has an IND for noribogaine (DMX-1001), not ibogaine itself. The handful of academic centers running trials aren’t set up as suppliers. Most ibogaine available in the world moves through chemical suppliers and import channels, not IND-holding manufacturers. Until one of them explicitly opts into RTT, the pathway is nearly theoretical.

And even if that supply problem were solved, there’s a legal precedent that makes the whole pathway shakier than advocates acknowledge. In 2021, Dr. Sunil Aggarwal sued the DEA after it refused to let him treat terminally ill cancer patients with psilocybin under Right to Try. The first Ninth Circuit panel dismissed on jurisdictional grounds (the DEA’s letter wasn’t a reviewable decision). A subsequent ruling went to the merits and the result was the same: Right to Try doesn’t override Schedule I restrictions, and physicians who aren’t DEA-registered researchers don’t get Schedule I access just because a patient qualifies. That ruling was about psilocybin, but ibogaine is Schedule I by the same authority. The legal argument for RTT access to ibogaine runs directly into the same wall.

Set that aside for a moment and look at who would qualify on the patient side, assuming both problems were solved.

Fentanyl OUD makes the strongest case. Overdose mortality is documented, the statistics are not contestable, and the patient population has often failed suboxone or methadone repeatedly. The contested term is “exhausted approved treatments”: a physician or insurance company can argue that medication-assisted treatment is still available, just declined. Whether that interpretation holds up in a real clinical or legal context is an open question. The IBOGAINE Act (H.R. 9559, introduced June 30) is specifically trying to settle this by clarifying eligibility for OUD and PTSD patients. It hasn’t passed.

PTSD qualifies more narrowly. You’d need documented treatment failure across multiple SSRIs, documented failed psychotherapy, and ideally documented suicidal ideation. That’s a real patient (the veteran who shows up in the Stanford MISTIC data), but it’s a narrower population than the advocacy framing often implies.

Kratom dependency almost certainly doesn’t qualify. It doesn’t map cleanly to “life-threatening condition” under the DSM, and the mortality argument is harder to make than it is for fentanyl.

The cardiac math

Ibogaine prolongs the QT interval, the window in a heartbeat during which the heart’s electrical system resets. When that window extends too long, the rhythm can tip into torsades de pointes, a ventricular arrhythmia that can kill you in minutes.

How much does ibogaine extend the QT? One observational trial found an average prolongation of 95 milliseconds, with 50 percent of subjects hitting a QTc above 500ms. For context, methadone, already considered a high cardiac-risk medication, prolongs the QT by an average of 10 to 15 milliseconds. Ibogaine’s effect is roughly six to ten times larger.

Now layer in what fentanyl does to the same cardiac system. Fentanyl at chronic doses has its own QT-prolonging effects. Long-term fentanyl users frequently carry electrolyte imbalances (hypokalemia, hypomagnesemia) that independently worsen QT prolongation. And fentanyl is highly lipophilic: it accumulates in fat tissue, meaning a patient who reports being off fentanyl for two or three days may still have meaningful circulating levels when ibogaine is administered.

Add polydrug use, which is the norm rather than the exception in this population, and you introduce CYP2D6 inhibition risk: the enzyme ibogaine relies on for metabolism gets blocked by common substances, making ibogaine’s dose-response unpredictable in ways it wouldn’t be in a healthier patient.

The mortality data bears this out. A retrospective study of 19,071 patients treated across 11 international clinics found six deaths within 72 hours. All six were among patients treated for opioid use disorder. None occurred among the 8,689 non-substance-use-disorder patients in the same dataset.

This is almost certainly why Ambio Life Sciences (the Mexico facility where the Stanford MISTIC veterans were treated) updated its protocol after a patient death in January 2026 to require a minimum 21-day stay for fentanyl-dependent patients before ibogaine administration. The washout period is the difference between a survivable arrhythmia and a fatal one.

What the clinical trial setting provides

Clinical trials provide something Right to Try does not: continuous cardiac monitoring, mandatory washout periods, exclusion criteria that filter out the highest-risk patients before they ever receive a dose, and the infrastructure to intervene when QTc extends past the threshold that precedes a dangerous rhythm.

Right to Try, by design, moves the treatment outside that structure. A provider willing to administer ibogaine under Right to Try to an active fentanyl user may not have 24-hour ECG monitoring. They may not enforce a multi-week washout. They may not have the same exclusion criteria that kept the trial populations safer.

The law gives the highest-risk patients access. It doesn’t give them the risk-mitigation infrastructure that made ibogaine survivable for those patients in controlled settings.

So where does that leave patients?

The Stanford data holds up. The MISTIC results are peer-reviewed. The patients failing MAT and dying of fentanyl overdoses aren’t abstractions, and ibogaine’s potential for that population is meaningful.

But Right to Try is a conditional pathway, and the conditions that make it safe for fentanyl-dependent patients cost money and require infrastructure most solo practitioners don’t have. Opening the door isn’t the same as building what needs to be on the other side of it.

The advocacy space hasn’t fully worked that out yet.